J&J’s $6.5B Momenta Buy Pays Off With Phase II Sjögren’s Disease Win

[cafead]

via Johnson & Johnson on Saturday posted promising data from the Phase II DAHLIAS study of its investigational FcRn blocker nipocalimab, demonstrating significant symptomatic improvement in patients with the chronic autoimmune Sjögren’s disease.

article source